Cargando…

An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives

Profound progress has been made in cancer treatment in the past three decades. However, drug resistance remains prevalent and a critical challenge. Drug resistance can be attributed to oncogenes mutations, activated defensive mechanisms, ATP-bind cassette transporters overexpression, cancer stem cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Qingmei, Zhou, Xin, Ren, Han, Han, Fangxuan, Lin, Rong, Li, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582727/
https://www.ncbi.nlm.nih.gov/pubmed/37860119
http://dx.doi.org/10.3389/fphar.2023.1274336
_version_ 1785122396256075776
author Ye, Qingmei
Zhou, Xin
Ren, Han
Han, Fangxuan
Lin, Rong
Li, Juan
author_facet Ye, Qingmei
Zhou, Xin
Ren, Han
Han, Fangxuan
Lin, Rong
Li, Juan
author_sort Ye, Qingmei
collection PubMed
description Profound progress has been made in cancer treatment in the past three decades. However, drug resistance remains prevalent and a critical challenge. Drug resistance can be attributed to oncogenes mutations, activated defensive mechanisms, ATP-bind cassette transporters overexpression, cancer stem cells, etc. Chinese traditional medicine toad venom has been used for centuries for different diseases, including resistant cancers. Bufalin is one of the bufadienolides in toad venom that has been extensively studied for its potential in refractory and drug-resistant cancer treatments in vitro and in vivo. In this work, we would like to critically review the progress made in the past decade (2013–2022) of bufalin in overcoming drug resistance in cancers. Generally, bufalin shows high potential in killing certain refractory and resistant cancer cells via multiple mechanisms. More importantly, bufalin can work as a chemo-sensitizer that enhances the sensitivity of certain conventional and targeted therapies at low concentrations. In addition, the development of bufalin derivatives was also briefly summarized and discussed. We also analyzed the obstacles and challenges and provided possible solutions for future perspectives. We hope that the collective information may help evoke more effort for more in-depth studies and evaluation of bufalin in both lab and possible clinical trials.
format Online
Article
Text
id pubmed-10582727
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105827272023-10-19 An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives Ye, Qingmei Zhou, Xin Ren, Han Han, Fangxuan Lin, Rong Li, Juan Front Pharmacol Pharmacology Profound progress has been made in cancer treatment in the past three decades. However, drug resistance remains prevalent and a critical challenge. Drug resistance can be attributed to oncogenes mutations, activated defensive mechanisms, ATP-bind cassette transporters overexpression, cancer stem cells, etc. Chinese traditional medicine toad venom has been used for centuries for different diseases, including resistant cancers. Bufalin is one of the bufadienolides in toad venom that has been extensively studied for its potential in refractory and drug-resistant cancer treatments in vitro and in vivo. In this work, we would like to critically review the progress made in the past decade (2013–2022) of bufalin in overcoming drug resistance in cancers. Generally, bufalin shows high potential in killing certain refractory and resistant cancer cells via multiple mechanisms. More importantly, bufalin can work as a chemo-sensitizer that enhances the sensitivity of certain conventional and targeted therapies at low concentrations. In addition, the development of bufalin derivatives was also briefly summarized and discussed. We also analyzed the obstacles and challenges and provided possible solutions for future perspectives. We hope that the collective information may help evoke more effort for more in-depth studies and evaluation of bufalin in both lab and possible clinical trials. Frontiers Media S.A. 2023-10-04 /pmc/articles/PMC10582727/ /pubmed/37860119 http://dx.doi.org/10.3389/fphar.2023.1274336 Text en Copyright © 2023 Ye, Zhou, Ren, Han, Lin and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ye, Qingmei
Zhou, Xin
Ren, Han
Han, Fangxuan
Lin, Rong
Li, Juan
An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
title An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
title_full An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
title_fullStr An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
title_full_unstemmed An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
title_short An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
title_sort overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582727/
https://www.ncbi.nlm.nih.gov/pubmed/37860119
http://dx.doi.org/10.3389/fphar.2023.1274336
work_keys_str_mv AT yeqingmei anoverviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives
AT zhouxin anoverviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives
AT renhan anoverviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives
AT hanfangxuan anoverviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives
AT linrong anoverviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives
AT lijuan anoverviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives
AT yeqingmei overviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives
AT zhouxin overviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives
AT renhan overviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives
AT hanfangxuan overviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives
AT linrong overviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives
AT lijuan overviewofthepastdecadeofbufalininthetreatmentofrefractoryanddrugresistantcancerscurrentstatuschallengesandfutureperspectives